Article
Expression of the potyvirus coat protein mediated by recombinant vaccinia virus and assembly of potyvirus-like particles in mammalian cells.
CSIRO, Australian Animal Health Laboratory, Geelong, Victoria, Australia.
Archives of Virology (impact factor:
2.11).
02/1998;
143(7):1433-9.
pp.1433-9
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: DNA vaccines based on chimeric potyvirus-like particles carrying HPV16 E7 peptide (aa 44-60).
[show abstract] [hide abstract]
ABSTRACT: Vaccine strategies for the treatment of human papillomavirus-induced cervical cancer are based mainly on the human papillomavirus 16 E7 (HPV16 E7) oncoprotein. The immunogenicity of the E7 gene has been enhanced by its fusion to many different genes. Here, we linked a short sequence coding for the E7 peptide (aa 44-60) containing immunodominant epitopes for B and T cells to the 3' end of the gene coding for the whole coat protein (CP) of the poty-virus, potato virus A (PVA), and its deleted form (CPdel) with a short C-terminal deletion of 5 amino acids (LGVKG). CP-E7 and CPdel-E7 fusion proteins, just like CP alone, spontaneously assembled into virus-like particles in both procaryotic and eucaryotic cells. The CP-E7 and CPdel-E7 fusion genes induced slightly stronger E7-specific cytotoxic T-lymphocyte responses than the whole E7 gene, although they were still lower than those elicited by the previously constructed fusion gene, Sig/E7GGG/LAMP-1. The E7- and CP-specific antibody responses were not detected in mice vaccinated with CP-E7 and CPdel-E7 fusion genes. The CP-E7 and CPdel-E7 fusion genes protected mice against the development of tumors induced by TC-1 cells producing the E7 antigen and were also effective in the therapeutic setting, i.e. when the vaccination was performed after tumor cell administration. Their antitumor effect was comparable to those of the whole E7 gene and Sig/E7GGG/LAMP-1 fusion gene. There was no relevant difference between immune responses elicited by CP-E7 and CPdel-E7 DNA vaccination.Oncology Reports 11/2005; 14(4):1045-53. · 1.84 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
additional VV recombinants
C-terminal extensions
coat protein
Johnsongrass mosaic virus
N-terminal
oral administration
particle purification
potyvirus
potyvirus coat protein
potyvirus-like particles
poxviruses
proven advantages
PVLP formation
recombinant vaccinia virus
recombinant VV
sufficient levels
Ultra-thin section electron microscopy
vaccine antigens
vaccine strategy
vaccines